CoChat

The future of immune checkpoint therapy

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.

Abstract

Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clinical advances and provided a new weapon against cancer. This therapy has elicited durable clinical responses and, in a fraction of patients, long-term remissions where patients exhibit no clinical signs of cancer for many years. The way forward for this class of novel agents lies in our ability to understand human immune responses in the tumor microenvironment. This will provide valuable information regarding the dynamic nature of the immune response and regulation of additional pathways that will need to be targeted through combination therapies to provide survival benefit for greater numbers of patients.

Overview

Integrity signals

Registry

Crossref · 10.1126/science.aaa8172

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 70 references

Cited by

Items 201–300 of 419

Metadata

Authors
Sharma, P., & Allison, J. P.
Affiliations
The University of Texas MD Anderson Cancer Center (US)
Corresponding author
  • Sharma, Padmanee
  • Allison, James P.
Venue
Science
Published
2015-04-03
Volume
348
Issue
6230
Pages
56-61
ISSN
  • 0036-8075 (ISSN-L)
  • 1095-9203
OpenAlex
W2060070314
Cited by
4,878
References
70
Citations by year
2026: 311 · 2025: 372 · 2024: 398 · 2023: 462 · 2022: 473 · 2021: 576 · 2020: 569 · 2019: 455 · 2018: 444 · 2017: 401 · 2016: 294 · 2015: 113
FWCI
44.39
Type
journal article
Language
en
Open access
closed
Locations
  • Science (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Cancer Prevention Research in Texas
  • PCF Challenge Grant in Immunology
  • NCI/NIH (1-R01 CA1633793-01)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
immune checkpoint inhibitors, cancer immunotherapy, tumor microenvironment, antitumor immunity, T cell regulation, combination therapy, sustained remission
MeSH terms
Ipilimumab, Nivolumab, Antibodies, Monoclonal, Antineoplastic Agents, Combined Modality Therapy, Humans, Immunotherapy, Lymphocyte Activation, Neoplasms, T-Lymphocytes, Signal Transduction, Biomarkers, Pharmacological, Tumor Microenvironment, Inducible T-Cell Co-Stimulator Protein, CTLA-4 Antigen, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.